Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study.
Viktor Grünwald(Deutsche Schmerzgesellschaft), Burghardt Wittig, Stefan Hauser(German Center for Neurodegenerative Diseases), Manuel Schmidt(Mologen (Germany)), Ahmed Magheli(Johns Hopkins University), Ingo G.H. Schmidt‐Wolf(University Hospital Bonn), Steffen Weikert(St. Hedwig-Krankenhaus), Matthias Schroff(Mologen (Germany))
Cited by 7
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
|Journal of Clinical Oncology|2011|450
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431